Mark Norman Levine
#115,394
Most Influential Person Now
Mark Norman Levine's AcademicInfluence.com Rankings
Mark Norman Levinemedical Degrees
Medical
#1643
World Rank
#2006
Historical Rank
Oncology
#78
World Rank
#82
Historical Rank
Epidemiology
#252
World Rank
#269
Historical Rank
Mark Norman Levinephilosophy Degrees
Philosophy
#4995
World Rank
#7691
Historical Rank
Logic
#2345
World Rank
#3321
Historical Rank
Download Badge
Medical Philosophy
Mark Norman Levine's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Epidemiology University of California, Berkeley
Why Is Mark Norman Levine Influential?
(Suggest an Edit or Addition)Mark Norman Levine's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. (2003) (2222)
- Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. (1995) (2216)
- Prevention of venous thromboembolism. (1995) (1817)
- Hemorrhagic complications of anticoagulant treatment. (1992) (1263)
- A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. (1996) (1191)
- Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013) (998)
- Long-term results of hypofractionated radiation therapy for breast cancer. (2010) (978)
- American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. (2007) (953)
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018) (844)
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. (2020) (757)
- Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. (2015) (732)
- Venous Thromboembolism and Cancer: Risks and Outcomes (2003) (718)
- Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (701)
- Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). (2004) (666)
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. (1998) (612)
- Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. (1993) (549)
- A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. (1986) (537)
- HER2 and responsiveness of breast cancer to adjuvant chemotherapy. (2006) (537)
- Regional Nodal Irradiation in Early-Stage Breast Cancer. (2015) (523)
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. (1995) (495)
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer (1994) (483)
- Responsiveness and validity in health status measurement: a clarification. (1989) (478)
- Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. (2005) (475)
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. (2017) (438)
- The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. (1988) (430)
- Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. (2007) (418)
- Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. (1996) (417)
- Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. (1992) (397)
- Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. (1986) (390)
- Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis (1995) (383)
- Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. (2003) (371)
- A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. (1994) (370)
- Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (367)
- Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. (2005) (367)
- Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. (2002) (367)
- Regional Nodal Irradiation in Early-Stage Breast Cancer. (2015) (350)
- A standard heparin nomogram for the management of heparin therapy. (1991) (341)
- Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. (2013) (335)
- Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. (2006) (318)
- Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. (1991) (310)
- Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. (2011) (309)
- Randomized Trial of Breast Irradiation Schedules After Lumpectomy for Women With Lymph Node-Negative Breast Cancer (2002) (303)
- Radiation therapy and tamoxifen: concurrent or sequential? That is the question. (2005) (302)
- A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. (1990) (298)
- A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. (1992) (294)
- Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. (2006) (282)
- Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. (2013) (282)
- NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (2011) (266)
- Hemorrhagic complications of anticoagulant treatment. (2004) (231)
- Quality of life in stage II breast cancer: an instrument for clinical trials. (1988) (227)
- PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma (2010) (227)
- A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. (1989) (224)
- Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread (1999) (222)
- DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE (1987) (210)
- Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. (2005) (209)
- The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement (1989) (208)
- Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. (2009) (202)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Risks to the Fetus of Anticoagulant Therapy During Pregnancy (1989) (197)
- External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial (2019) (197)
- Hemorrhagic complications of long-term anticoagulant therapy. (1989) (194)
- Epidemiology of Thrombosis in Cancer (2001) (194)
- The thrombophilic state induced by therapeutic agents in the cancer patient. (1999) (187)
- Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy (2004) (176)
- Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. (1987) (173)
- Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. (1994) (172)
- Hemorrhagic complications of anticoagulant therapy. (1986) (171)
- Optimal therapeutic range for oral anticoagulants. (1989) (168)
- Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. (1996) (167)
- Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. (1998) (166)
- The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. (1993) (160)
- Efficacy and Cost of Low-Molecular-Weight Heparin Compared with Standard Heparin for the Prevention of Deep Vein Thrombosis after Total Hip Arthroplasty (1993) (150)
- Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. (2014) (147)
- Hemostatic alterations in cancer patients. (1992) (144)
- Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. (2014) (143)
- Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. (1994) (142)
- Clinical Utility of a Rapid Whole-Blood d-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis (1999) (141)
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial (2012) (141)
- Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. (2004) (137)
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. (2010) (137)
- The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical Oncology Group. (2000) (137)
- Defining breast cancer intrinsic subtypes by quantitative receptor expression. (2015) (136)
- Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. (1999) (130)
- Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment (2008) (130)
- Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. (2013) (128)
- Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial (2011) (127)
- Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. (2005) (126)
- Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1989) (123)
- Hemostatic alterations in cancer patients (2005) (123)
- Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. (1990) (119)
- Breast irradiation postlumpectomy: development and evaluation of a decision instrument. (1995) (116)
- A Prospective Evaluation of Positron Emission Tomography Scanning, Sentinel Lymph Node Biopsy, and Standard Axillary Dissection for Axillary Staging in Patients with Early Stage Breast Cancer (2004) (115)
- Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. (2006) (115)
- Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. (1996) (111)
- Positron Emission Tomography in Staging Early Lung Cancer (2009) (111)
- A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. (1992) (108)
- Claudin-Low Breast Cancer; Clinical & Pathological Characteristics (2017) (103)
- An Evaluation of Impedance Plethysmography and 125I-Fibrinogen Leg Scanning in Patients following Hip Surgery (1989) (102)
- Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. (1997) (101)
- Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer☆ (2003) (97)
- Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. (1996) (95)
- Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. (1999) (93)
- Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. (1994) (91)
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. (2014) (89)
- Registries that show efficacy: good, but not good enough. (2008) (87)
- The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. (1992) (86)
- Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. (2003) (86)
- Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. (1996) (85)
- Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. (2012) (84)
- The Effect of Very-low-dose Warfarin on Markers of Hypercoagulation in Metastatic Breast Cancer: Results from a Randomized Trial (1998) (84)
- Venous Thromboembolism in Malignancy and Malignancy in Venous Thromboembolism (1998) (81)
- A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial (2015) (81)
- Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios (2011) (75)
- A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty (1992) (75)
- Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. (2005) (72)
- Thrombotic disorders: diagnosis and treatment. (2003) (70)
- Guidelines for Clotting Studies in Cancer Patients (1993) (69)
- When is a prognostic factor useful? A guide for the perplexed. (1991) (68)
- Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. (2017) (68)
- Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. (1988) (68)
- The Occurrence of Subsequent Malignancy in Patients Presenting with Deep Vein Thrombosis: Results from a Historical Cohort Study (1998) (65)
- Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. (2016) (65)
- Beyond the development of quality-of-life instruments: where do we go from here? (2002) (65)
- Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. (1986) (62)
- Low molecular weight heparin (2014) (62)
- Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. (1992) (62)
- Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. (2005) (61)
- Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. (2009) (60)
- Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. (2015) (59)
- Chemotherapy enhances endothelial cell reactivity to platelets (1990) (58)
- Thrombolytic therapy for venous thromboembolism. Complications and contraindications. (1995) (56)
- Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. (2008) (56)
- Heparin-induced thrombocytopenia. (1986) (56)
- Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. (1986) (55)
- The diagnosis and treatment of thrombosis in the cancer patient. (1990) (54)
- Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial (2018) (54)
- The optimal intensity of oral anticoagulant therapy. (1987) (53)
- Confusion Over the Therapeutic Range for Monitoring Oral Anticoagulant Therapy in North America (1988) (53)
- A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. (1990) (51)
- Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. (1990) (51)
- Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia (1995) (51)
- Comparative effectiveness research in oncology: an overview. (2012) (49)
- Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial (2014) (49)
- The importance of reporting patient recruitment details in phase III trials. (2006) (45)
- Adjuvant chemotherapy for breast cancer--30 years later. (2006) (45)
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial (2011) (43)
- More evidence that locoregional radiation therapy improves survival: what should we do? (2005) (43)
- Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. (1985) (43)
- Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. (1997) (43)
- Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m) (2020) (42)
- Treatment of thrombotic disorders in cancer patients. (1997) (42)
- Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. (1995) (42)
- Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. (1989) (40)
- A Randomized Controlled Trial of Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery (1987) (39)
- A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study (2001) (39)
- Lessons learned from the Decision Board: a unique and evolving decision aid (2000) (39)
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study (2014) (38)
- PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma (2007) (38)
- Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. (1983) (38)
- Long-term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation Following Breast Conserving Surgery in Women with Node-Negative Breast Cancer (2008) (37)
- Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). (2006) (36)
- Low molecular weight heparin: laboratory properties and clinical evaluation. A review. (1994) (36)
- Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients (2011) (34)
- Thrombolytic therapy for the treatment of acute pulmonary embolism. (1992) (33)
- A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. (1992) (30)
- Nonhemorrhagic complications of anticoagulant therapy. (1986) (30)
- Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1995) (29)
- New antithrombotic drugs: potential for use in oncology. (2009) (29)
- Catheter-associated thrombosis: thromboprophylaxis or not? (2005) (29)
- Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. (2012) (28)
- Management of venous thromboembolism in cancer patients. (2000) (28)
- Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. (2011) (28)
- The cluster-randomized Quality Initiative in Rectal Cancer trial: evaluating a quality-improvement strategy in surgery (2010) (28)
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. (2018) (27)
- Expectant management versus immediate treatment for low‐grade cervical intraepithelial neoplasia (2011) (27)
- Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. (2002) (27)
- 2005 The effect of delay in initiating radiotherapy post-lumpectomy on local breast recurrence (1996) (27)
- Surgical outcomes in women with ovarian cancer. (2008) (27)
- Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial (2008) (26)
- Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. (2002) (25)
- Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgeries for Cancer: A Prospective Cohort Study (2018) (25)
- Clinical use of low molecular weight heparins and heparinoids. (1988) (25)
- Anthracycline adjuvant chemotherapy: how much is enough? (2001) (25)
- Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial. (1988) (25)
- A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21) (2007) (25)
- Trastuzumab cardiac side effects: only time will tell. (2005) (25)
- Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. (2002) (25)
- Evidence-based approach to the introduction of positron emission tomography in ontario, Canada. (2009) (24)
- Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial (2011) (24)
- Cost effectiveness of a survivorship care plan for breast cancer survivors. (2014) (24)
- Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group. (1997) (24)
- Prevention of thrombosis in ambulatory patients with cancer. (2009) (24)
- Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group. (1997) (24)
- Cost-effectiveness of a survivorship care plan for breast cancer survivors. (2011) (23)
- The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. (1992) (23)
- Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay. (2017) (23)
- Abstract GS4-03: RAPID: A randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT) (2019) (23)
- Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials (2017) (22)
- Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC). (2011) (21)
- NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (2011) (21)
- The HER-2/neu oncogene in breast cancer: so what is new? (1992) (21)
- American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. (2007) (20)
- Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. (2011) (20)
- Optimal therapeutic range for oral anticoagulants [published erratum appears in Chest 1989 Oct;96(4):962] (1989) (20)
- Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer (2015) (20)
- Hemorrhagic complications of anticoagulant treatment. (2001) (20)
- Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial (2017) (19)
- Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer. (1994) (19)
- Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases (2019) (19)
- A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. (2016) (19)
- Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent (1992) (17)
- An overview of clinical trials of low molecular weight heparin fractions. (1989) (17)
- A Randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). (2002) (17)
- The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal‐based and cell‐based models (2011) (17)
- Treatment of Venous Thrombosis in the Cancer Patient (2001) (17)
- A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. (1990) (17)
- Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. (2015) (17)
- Adjuvant therapy and thrombosis: how to avoid the problem? (2007) (17)
- Funding oncology clinical trials: are cooperative group trials sustainable? (2012) (17)
- An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). (2011) (16)
- Recruitment for an efficacy study in chemoprevention--the Concerned Smoker Study. (1989) (16)
- Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials (2013) (15)
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer (2015) (15)
- Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients (2005) (15)
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. (2017) (15)
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt‐PA for pulmonary embolism (1997) (15)
- Uptake of an innovation in surgery: observations from the cluster-randomized Quality Initiative in Rectal Cancer trial. (2013) (15)
- Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (2011) (15)
- A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. (2019) (14)
- 15 Side-effects of antithrombotic therapy (1990) (14)
- Treatment of venous thromboembolism in cancer patients. (2001) (13)
- Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. (2012) (13)
- Clinical Practice Guidelines ( 8 th Edition ) College of Chest Physicians Evidence-Based and Thrombolytic Treatment : American Hemorrhagic Complications of Anticoagulant (2008) (13)
- Acquired alteration in the expression of blood groups in a patient with sideroblastic anemia and chronic renal failure (1984) (13)
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). (2022) (13)
- Hemorrhagic complications of long-term anticoagulant therapy. (1989) (13)
- Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). (2015) (12)
- Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriers. (2015) (12)
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. (2011) (12)
- Treatment of venous thromboembolism in cancer patients. (1998) (12)
- Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune (1987) (12)
- Risk of haemorrhage associated with long term anticoagulant therapy (1985) (12)
- The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery (2008) (12)
- Use of screening phase data to evaluate observer variation of sputum cytodiagnosis as an outcome measure in a chemoprevention trial. (1990) (11)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (11)
- Etretinate blood levels in monitoring of compliance and contamination in a chemoprevention trial. (1989) (11)
- Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial (2008) (11)
- Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. (2006) (10)
- Breast cancer consensus meetings: vive la difference? (2002) (10)
- Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. (1991) (10)
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study (2015) (10)
- neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II. (2003) (10)
- The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures (2016) (9)
- The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer (2005) (9)
- A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) (2008) (9)
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer. (2016) (9)
- Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE) (2003) (9)
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer (2018) (9)
- Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question (2006) (8)
- Effect of PET‐CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long‐term results of a randomized controlled trial (2020) (8)
- Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. (2009) (8)
- A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. (2007) (8)
- Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis (2019) (8)
- Risks and benefits of anticoagulant therapy. (1986) (8)
- Therapeutic range for the control of oral anticoagulant therapy. (1986) (8)
- Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START). (2009) (8)
- Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study (2013) (8)
- Epirubicin in breast cancer: present and future. (2000) (8)
- Side-effects of antithrombotic therapy. (1990) (8)
- Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. (2016) (7)
- A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials (2015) (7)
- Home-treatment of deep vein thrombosis in patients with cancer. (2005) (7)
- Statement from the Work Session on Environmentally induced Alterations in Development: A Focus on Wildlife (1995) (7)
- PO-40 PRODIGE: a randomized placebo-controlled trial of long-term thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma: updated results (2007) (7)
- Survival results from a phase III study of simultaneous versus 1-hour sequential methotrexate-5-fluorouracil chemotherapy in head and neck cancer. (1986) (7)
- Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial. (2016) (7)
- Risk Assessment and Primary VTE Prevention in the Cancer Patient (2003) (7)
- Economics of preoperative radiotherapy with total mesorectal excision: what can we learn from the Dutch experience? (2004) (7)
- Simultaneous resection of colorectal cancer with synchronous liver metastases (RESECT), a pilot study (2018) (7)
- Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. (2003) (6)
- Researching the cost of research. (2003) (6)
- The value of postoperative red cell transfusions is unclear (1993) (6)
- Hypofractionated Breast Irradiation: What's Next? (2020) (6)
- Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap. (1986) (6)
- Pilot Study of the Quality Initiative in Rectal Cancer Strategy (2004) (6)
- Learning Health System for Breast Cancer: Pilot Project Experience. (2019) (6)
- Better treatments that cost more: the dilemma. (2000) (6)
- What is the role for antithrombotics in cancer care? Interactive session with panel discussion. (2002) (6)
- Conventional and complementary therapies: a tale of two research standards? (2010) (5)
- Imaging: PET–CT imaging in non-small-cell lung cancer (2009) (5)
- S35 CEF versus CMF in premenopausal women — Recent update (1998) (5)
- The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer (2012) (5)
- OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy (2010) (5)
- Management of thromboembolic disease in cancer patients. (2001) (5)
- TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial (2015) (5)
- The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. (2011) (5)
- Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial (2016) (5)
- Clinical Use of the Heparin Nomogram-Reply (1991) (5)
- Clinical potential of low molecular weight heparins. (1990) (5)
- Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer (2014) (5)
- The clinical practice guideline: an evolving health care technology. (1997) (5)
- Treatment of Venous Thromboembolism in Cancer Patients (1998) (5)
- Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience (2020) (5)
- Local breast recurrence (lbr) post-lumpectomy is predictive of subsequent mortality: Results from a randomized trial (1993) (5)
- 4 Clinical potential of low molecular weight heparins (1990) (5)
- Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer. (2006) (4)
- Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer (2014) (4)
- An Ontario Clinical Oncology (OCOG) Randomized Trial (PET START) of FDG PET/CT in Stage 3 Non-small Cell Lung Cancer (NSCLC): Impact of PET on Survival (2011) (4)
- Radiotherapy for breast cancer. (2002) (4)
- A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer (2008) (4)
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. (2015) (4)
- Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. (2010) (4)
- 99 The effects of radiation therapy on quality of life in women with breast cancer: Results of a randomized trial (1997) (4)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (4)
- Re: Is less more? Lessons in radiation schedules in breast cancer. (2003) (3)
- Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1992) (3)
- Method to our madness or madness in our methods? Pitfalls in trial methodology. (2012) (3)
- Epilogue: the peril and the promise of comparative effectiveness research in oncology. (2012) (3)
- The premarket assessment of the cost-effectiveness of a predictive technology “Straticyte™” for the early detection of oral cancer: a decision analytic model (2017) (3)
- Risk of Haemorrhage Associated with Long Term (1985) (3)
- Quality of Life in Breast Cancer (2021) (3)
- Chemoprevention for lung cancer--evidence for a high degree of compliance. (1990) (3)
- Abstract Tenth annual meeting of the society for clinical trials May 15–18, 1989 Hyatt Regency Minneapolis, Minneapolis, MinnesotaQuality of life in stage 2 breast cancer patients measured by a time trade off method (1989) (3)
- P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity. (2011) (3)
- Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). (2010) (3)
- An overview of clinical trials of low molecular weight heparin fractions. (1988) (3)
- Survival analysis of PETCAM: A multicenter randomized controlled trial of PET/CT versus no PET/CT for patients with resectable liver colorectal adenocarcinoma metastases. (2012) (3)
- Thrombolytic therapy in acute pulmonary embolism. (1993) (3)
- How long to treat acute venous thrombosis in cancer: can treatment be personalized? (2014) (2)
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases (2005) (2)
- Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectoscope. (2014) (2)
- Reduced tumour response and survival among patients with head and neck cancer who continue to smoke during radiation therapy (1990) (2)
- 357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors (2012) (2)
- Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. (2011) (2)
- PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial. (2016) (2)
- A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial (2016) (2)
- Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. (2014) (2)
- Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (2014) (2)
- P82 Efficacy of double-blinding in a randomized controlled trial (RCT) of low dose warfarin to prevent thromboembolic disease in patients with metastatic breast cancer (1993) (2)
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer (2004) (2)
- Clinical decision making vs programme evaluation perspectives. (1993) (2)
- Prospective Cohort Study of the Incidence, Risk Factors and Long-Term Sequelae of Symptomatic Catheter-Related Thrombosis in Adults with Cancer. (2004) (2)
- Thromboembolic risk of tamoxifen in patients with stage II breast cancer. (1989) (2)
- PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies (1997) (1)
- Thromboprophylaxis during chemotherapy: NO. (2010) (1)
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464) (2020) (1)
- P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. (2011) (1)
- A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke (2020) (1)
- Hemorrhagic complications of anticoagulant treatment. (1998) (1)
- EVALUATION OF THE ACCURACY OF A 99MTC-LABELLED MONOCLONAL ANTIBODY SPECIFIC FOR D-DIMER IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS (DVT) (2007) (1)
- Radiation therapy following breast conservation surgery: can it ever be avoided? (1997) (1)
- Post radiotherapy biopsy correlation with PSA failure: Results from a randomized hypofractionated study in localized prostate cancer (2004) (1)
- 169 The impact of positron emission tomography (PET) in stage III non-small cell lung cancer: A prospective randomized clinical trial-improving clinical trials accrual using screening log evaluations (2006) (1)
- Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases). (2018) (1)
- Treating clots in cancer: moving closer to an answer? (2014) (1)
- Risk Factors for Thrombosis and Bleedings Prevention of Arterial and Venous Thrombosis Treatment of VTE and Adverse Reactions (1999) (1)
- Abstract of the 12th International Congress on Thrombosis Plenary lectures of the 12th International Congress on Thrombosis Plenary lectures of the 12tLimitations of impedance plethysmography (IPG) in the diagnosis of clinically suspected deep-vein thrombosis (DVT) (1992) (1)
- Can we optimise treatment of thrombosis? (2003) (1)
- Prevention of Cancer-Associated Thrombosis: An Overview (2004) (1)
- Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trial. (2013) (1)
- Routine Imaging or No Routine Imaging, Is That the Question? (2020) (1)
- Interim analysis for binary outcome trials with a long fixed follow-up time and repeated outcome assessments at pre-specified times (2014) (1)
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study. (2012) (1)
- Treatment of first episode of venous thrombosis. (1987) (1)
- PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC). (2009) (1)
- Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial. (2018) (1)
- Arm lymphedema in breast cancer patients: Is it always related to treatment (2004) (1)
- A Randomized Trial of Less Intense Postoperative Warfarin or Aspirin Therapy in the Prevention of Venous Thromboembolism After Surgery for Fractured Hip (1990) (0)
- Other Uses of LMWHs – Miscellaneous (1998) (0)
- Chapter 23 – Thrombosis and Cancer (2007) (0)
- Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer (2015) (0)
- A questionnaire to measure morbidity in patients receiving radiation therapy for head and neck cancer (1992) (0)
- Venous Thromboembolism and Its Treatment in High-Risk Groups (2003) (0)
- PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial (2021) (0)
- Abstract P4-12-09: The immune response in triple negative breast cancer (2017) (0)
- Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study (2012) (0)
- Nonclinical factors in patient selection for surgery (2001) (0)
- Abstract A124: Characterization of claudin-low breast cancers (2013) (0)
- Eligible-non-randomized patients: Their impact on generalizability (1992) (0)
- Monitoring compliance and contamination in a chemoprevention trial (1989) (0)
- P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. (2011) (0)
- Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
- Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
- S40 Adjuvant therapies and thrombosis: How to avoid the problem? (2007) (0)
- Venous thromboembolism and its treatment in high-risk groups - Preface (2003) (0)
- Hemostatic changes in canger (1992) (0)
- Title Page / Contents / Preface (1999) (0)
- P-selectin ready for prime time? (2009) (0)
- Abstract P2-05-05: A four gene signature predicts anthracycline benefit: Evidence from the BR9601 and MA5 breast cancer trials (2015) (0)
- Treatment of locally advanced breast cancer (2004) (0)
- 30 PET START: THE FIRST RANDOMIZED CLINICAL TRIAL EVALUATING THE IMPACT OF POSITRON EMISSION TOMOGRAPHY IN STAGE III NON-SMALL CELL LUNG CANCER (2009) (0)
- A randomized trial comparing combination of iridium implant and external beam radiation vs. external beam radiation alone in node negative locally advanced cancer of the prostate: Preliminary report (1998) (0)
- P81 A trial evaluating the home treatment of patients with acute proximal deep vein thrombosis (DVT) (1995) (0)
- Abstract P3-12-02: Lifestyle interventions combined with acupuncture-like transcutaneous electrical nerve stimulation in managing vasomotor symptoms induced by breast cancer treatment: Results of a phase 2 randomized controlled trial (2015) (0)
- Standardization of Heparin Therapy Improves Efficacy-Reply (1992) (0)
- LETTER TO THE EDITOR REGARDING WHELAN ET AL., IJROBP 30:1-16; 1994. AUTHOR'S REPLIES (1995) (0)
- Outcomes of postmastectomy radiotherapy (2005) (0)
- A review and appraisal of thirty years research on cereal uredinology in Italy. (1960) (0)
- Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials (2021) (0)
- Theeffect ofthesynthetic retinoid etretinate onsputum cytology: results froma randomised trial (1992) (0)
- Preface to Special Edition on Breast Cancer (2005) (0)
- FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study. (2023) (0)
- Funding academic oncology clinical trials. (2011) (0)
- Impact of a randomized trial on transfusion practice in orthopedic surgery (1992) (0)
- Moderate Renal Impairment and Risk of Bleeding With Anticoagulation (2017) (0)
- Abstract PD12-01: Evaluation of sleep problems and their association with febrile neutropenia, leucopenia and infections in women receiving adjuvant chemotherapy for breast cancer in the Canadian Cancer Trials Group MA.21 trial (2021) (0)
- Significance: Clinical or Statistical?-Rebuttal (1989) (0)
- Author reply (1997) (0)
- Thromboembolism: New Achievements and Challenges: 6th International Symposium on Thromboembolic Diseases, Lisbon, June 1999: Proceedings (1999) (0)
- The Role of Aggressive Surgery in Advanced Epithelial Ovarian Cancer (2001) (0)
- Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
- Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
- Positron Emission Tomography in Staging Early Lung CancerA Randomized Trial (2009) (0)
- ImpactFactor PET – CT imaging in non-small-cell lung cancer (2009) (0)
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. (2014) (0)
- Author and Subject Index (2001) (0)
- Ontario oncology trials to evaluate the clinical and economic impact of 18-FDG PET (2008) (0)
- Introduction: building on a heritage in thrombosis – perspectives in cancer care (2002) (0)
- Risk o f A cute L eukemia F ollowing E pirubicin-Based A djuvant Chemotherapy: A R eport F rom t he N ational C ancer I nstitute o f Canada C linical T rials G roup (2003) (0)
- In response to Drs. Yaes and Yu (1995) (0)
- 2190 Longer term follow-up of a prospective, randomized placebo controlled trial of concomitant chemotherapy and radiation vs radiation alone for advanced stage head and neck cancers (1999) (0)
- Subject Index Vol. 37, 2009–10 (2011) (0)
- Breast Cancer (2012) (0)
- Selective application of a test based on risk: using limited resources wisely. (2013) (0)
- [Current knowledge concerning the etiology of acute infantile diarrhea]. (1983) (0)
- Abstract P2-10-01: Validation that a histone gene signature predicts anthracycline response in early breast cancer (2018) (0)
- Contents Vol. 37, 2009–10 (2011) (0)
- Screening cancer patients for clinical trial eligibility: A randomized study (2007) (0)
- Title Page / Table of Contents, Vol. 27, Suppl. 1, 1997 (1997) (0)
- Other Uses of LMWHs – Miscellaneous (1998) (0)
- Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS) (2019) (0)
- The physiological basis of pelvic floor exercises in the treatment of stress urinary incontinence (1999) (0)
- Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial (2022) (0)
- Abstract P2-10-04: Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit (2018) (0)
- Comments, Opinions, and Reviews Hemorrhagic Complications of Long-Term Anticoagulant Therapy for Ischemic Cerebral Vascular Disease (1986) (0)
- What you may learn from the dutch experience (2005) (0)
- Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter : New tones for an old song. Author's reply (2005) (0)
- DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer (2009) (0)
- Prevention of Deep Vein Thrombosis after Elective Hip Surgery (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mark Norman Levine?
Mark Norman Levine is affiliated with the following schools:
